TY - JOUR
T1 - Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection and vaccination
AU - Datta, Pratik
AU - Ukey, Rahul
AU - Bruiners, Natalie
AU - Honnen, William
AU - Carayannopoulos, Mary O.
AU - Reichman, Charles
AU - Choudhary, Alok
AU - Onyuka, Alberta
AU - Handler, Deborah
AU - Guerrini, Valentina
AU - Mishra, Pankaj K.
AU - Dewald, Hannah K.
AU - Lardizabal, Alfred
AU - Lederer, Leeba
AU - Leiser, Aliza L.
AU - Hussain, Sabiha
AU - Jagpal, Sugeet K.
AU - Radbel, Jared
AU - Bhowmick, Tanaya
AU - Horton, Daniel B.
AU - Barrett, Emily S.
AU - Xie, Yingda L.
AU - Fitzgerald-Bocarsly, Patricia
AU - Weiss, Stanley H.
AU - Woortman, Melissa
AU - Parmar, Heta
AU - Roy, Jason
AU - Dominguez-Bello, Maria Gloria
AU - Blaser, Martin J.
AU - Carson, Jeffrey L.
AU - Panettieri, Reynold A.
AU - Libutti, Steven K.
AU - Raymond, Henry F.
AU - Pinter, Abraham
AU - Gennaro, Maria Laura
N1 - Funding Information:
We thank the PHRI biosafety officers and the RBHS Institutional Biosafety committee for fast-track review and approval of laboratory protocols and practices related to handling of SARS-CoV-2 and infected biospecimens; the Rutgers Institutional Review Board for timely review and approval of COVID-19-related protocols for human subject protection; Daniel Fine and Steven Libutti for supporting the start of our COVID-19 work; and Nancy Reilly and the entire Rutgers Corona Cohort team that established a cohort from which some of the serum samples utilized in this study were obtained. This work was funded by National Institutes of Health grants R01 HL149450, R01 HL149450-S1, R01 AI158911, R61 HD105619, U01 AI122285-S1, P30 ES005022, K23 AR070286, and UL1 TR003017.
Funding Information:
We thank the PHRI biosafety officers and the RBHS Institutional Biosafety committee for fast-track review and approval of laboratory protocols and practices related to handling of SARS-CoV-2 and infected biospecimens; the Rutgers Institutional Review Board for timely review and approval of COVID-19-related protocols for human subject protection; Daniel Fine and Steven Libutti for supporting the start of our COVID-19 work; and Nancy Reilly and the entire Rutgers Corona Cohort team that established a cohort from which some of the serum samples utilized in this study were obtained. This work was funded by National Institutes of Health grants R01 HL149450 , R01 HL149450-S1, R01 AI158911, R61 HD105619 , U01 AI122285-S1 , P30 ES005022 , K23 AR070286 , and UL1 TR003017 .
Publisher Copyright:
© 2021
PY - 2021/12
Y1 - 2021/12
N2 - Monitoring the burden and spread of infection with the new coronavirus SARS-CoV-2, whether within small communities or in large geographical settings, is of paramount importance for public health purposes. Serology, which detects the host antibody response to the infection, is the most appropriate tool for this task, since virus-derived markers are most reliably detected during the acute phase of infection. Here we show that our ELISA protocol, which is based on antibody binding to the Receptor Binding Domain (RBD) of the S1 subunit of the viral Spike protein expressed as a novel fusion protein, detects antibody responses to SARS-CoV-2 infection and vaccination. We also show that our ELISA is accurate and versatile. It compares favorably with commercial assays widely used in clinical practice to determine exposure to SARS-CoV-2. Moreover, our protocol accommodates use of various blood- and non-blood-derived biospecimens, such as breast milk, as well as dried blood obtained with microsampling cartridges that are appropriate for remote collection. As a result, our RBD-based ELISA protocols are well suited for seroepidemiology and other large-scale studies requiring parsimonious sample collection outside of healthcare settings.
AB - Monitoring the burden and spread of infection with the new coronavirus SARS-CoV-2, whether within small communities or in large geographical settings, is of paramount importance for public health purposes. Serology, which detects the host antibody response to the infection, is the most appropriate tool for this task, since virus-derived markers are most reliably detected during the acute phase of infection. Here we show that our ELISA protocol, which is based on antibody binding to the Receptor Binding Domain (RBD) of the S1 subunit of the viral Spike protein expressed as a novel fusion protein, detects antibody responses to SARS-CoV-2 infection and vaccination. We also show that our ELISA is accurate and versatile. It compares favorably with commercial assays widely used in clinical practice to determine exposure to SARS-CoV-2. Moreover, our protocol accommodates use of various blood- and non-blood-derived biospecimens, such as breast milk, as well as dried blood obtained with microsampling cartridges that are appropriate for remote collection. As a result, our RBD-based ELISA protocols are well suited for seroepidemiology and other large-scale studies requiring parsimonious sample collection outside of healthcare settings.
KW - Breast milk
KW - COVID-19
KW - Microsampling
KW - Seroepidemiology
UR - http://www.scopus.com/inward/record.url?scp=85118329598&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118329598&partnerID=8YFLogxK
U2 - 10.1016/j.jim.2021.113165
DO - 10.1016/j.jim.2021.113165
M3 - Article
C2 - 34634317
AN - SCOPUS:85118329598
SN - 0022-1759
VL - 499
JO - Journal of Immunological Methods
JF - Journal of Immunological Methods
M1 - 113165
ER -